Go to Client Portal

Biofilm Basics and Beyond



May 31, 2023

Access On-Demand Webinar Here


Join NAMSA for an educational and engaging webinar that explores the widely unknown topic of biofilm. We discuss the serious health threat of biofilms to global health, the relationship between antimicrobial resistance (AMR) and biofilm and the In Vitro biofilm test models that reflect real-world challenges products face.

In nature, 80% of bacteria exist within a biofilm. When microorganisms live beneath a biofilm, they are significantly less susceptible to antimicrobial agents, antibiotics and the host’s immune system.

As it relates to medical device development, standard microbiological testing focuses almost exclusively on planktonic bacteria. This focus may lead to an underestimation of the quantity of active agent required to remove a microbial biofilm effectively. This is why testing against biofilms In Vitro is critical during preclinical development. If this step is skipped, it could lead to products failing during In Vivo testing or clinical trials.


Attendees of this webinar can expect to walk away with a better understanding of the following:

  • Biofilm basics-what they are and why they are an important consideration in preclinical testing
  • How biofilms impact medical device products
  • Various biofilm test models and recommendations



*By registering for this event, you are providing NAMSA consent to contact you directly regarding NAMSA’s services. The information you are providing will be processed by NAMSA to better understand your product needs and interests. At any time, you can submit a request to withdraw your consent for the use of information provided by you by contacting us at: communications@namsa.com. For additional information, please visit our Privacy Policy or contact us at privacy@namsa.com

NAMSA uses a third-party provider, GoToWebcast, to host NAMSA webinars. For information related to GoToWebcast’s privacy policy and utilization of information, please contact GoToWebcast directly.


Hannah Thomas

Principal Senior Scientist

Hannah joined NAMSA in 2022 through the acquisition of Perfectus Biomed. She has been with Perfectus since 2013 and has held roles including Quality Manager, Operations Manager and became Principal Senior Scientist in 2021. During her time with the company, she has led the team to be the first in the world to develop and accredit biofilm test methods to ISO 17025, led collaborative projects to conduct groundbreaking research into wound care, and played a critical role in obtaining GLP accreditation. An integral part of the team with a breadth of knowledge and expertise in designing customized test methods that support MedTech product innovation.

Stefania Fabbri, PhD

Senior Scientist

Stefania joined NAMSA via the acquisition of Perfectus Biomed in 2022. She has been with Perfectus since 2018 and brings extensive experience in biofilmology. Stefania studied Biomedical Engineering at the University of Genoa before moving to the University of Southampton. Her PhD focused on investigating interfacial instability generation in dental biofilms plus several post-doctoral placements specializing in marine biofilm decontamination.